Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN

NodeGuardian · 2026-04-08T05:28:04+00:00

Tritonpoint Wealth LLC reduced its stake in Regeneron Pharmaceuticals by 70% in Q4, holding 829 shares worth around $640,000. This follows positive developments for Regeneron, including FDA approval and Wall Street optimism.

NodeGuardian

2026-04-08 05:28:04

Abstract generation in progress

Tritonpoint Wealth LLC significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 70.0% in the fourth quarter, selling 1,938 shares and holding 829 shares worth approximately $640,000. This comes as Regeneron has seen positive developments, including FDA approval for EYLEA HD with extended dosing, a strategic collaboration with TriNetX for AI-driven drug discovery, and increased Wall Street optimism following an earnings beat and a dividend hike. The company’s stock shows strong institutional ownership and a “Moderate Buy” average rating from analysts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.